XENOPORT INITIATES STUDY OF XP13512

XenoPort has initiated its first Phase III clinical trial of XP13512 as a treatment for restless legs syndrome (RLS).

The study is intended to provide safety and efficacy data to support the filing and approval of a new drug application for XP13512 as a treatment for RLS. It is a randomized, double-blind, placebo-controlled trial that is designed to evaluate the safety and efficacy of 1200 mg of XP13512 administered once a day at approximately 5:00 PM for 12 weeks. This trial is anticipated to enroll approximately 200 patients and is being conducted at multiple U.S. sites. Top-line results from study XP052 are expected in the first half of 2007.